Course Experts: Addison Sember, PharmD and Ben Kematick, PharmD, BCACP

Course Description: This pharmacy law course outlines mitigation and communication strategies when providing care for patients with concomitant substance use disorder. Updates in medication delivery regulations and the Department of Health & Human Services opioid treatment program are reviewed.

[DFCI_KEYWORDS] Chronic Lymphocytic Leukemia (CLL), Bruton’s Tyrosine Kinase (BTK) Inhibitors, Pathophysiology, Prognostic Markers, Genetic Markers, Cytogenetics, Ibrutinib, Acalabrutinib, Zanubrutinib, Pirtobrutinib, Lymphocytes, Lymphadenopathy, Venetoclax, Obinutuzumab, Rituximab, Fludarabine, Bendamustine, Antiplatelet, Anticoagulation, Leukocytosis